Looking back at 2015: Our best MedHeads ever (you’ll never guess the guest)
Who would've realized this was just the beginning?
Who would've realized this was just the beginning?
Also, Novartis outlines a new future in drug pricing and get a deep drive into both Google Capital and GE Healthcare.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Ron Tilles, the chairman of the board for Turing Pharmaceuticals, has stepped up to replace Martin Shkreli as CEO.
The Shkreli affair, along with shenanigans from Valeant, have awakened serious journalists, who have started to look into drug pricing more broadly.
Martin Shkreli looked uncharacteristically somber during his perp walk on Thursday morning. Begs the question: Is this the end of Shkreli's ludicrous, smug antics? Nah.
However, U.S. Attorney Robert Capers says the investigation doesn't involve Martin Shkreli's price hike of Daraprim, and he's "not aware of where he got the funds for the Wu Tang album."
A lot of schadenfreude there.
For people who hate Shkreli for what he's done in 2015, this will be like the government getting Al Capone for tax evasion.
Also, some scientists are calling for a line to be drawn preventing edits to human genome that could be inherited.
Also, Dell jumped into the medical imaging market with its Dell medical Review 24 Monitor and Novo Nordisk said all of its global manufacturing facilities will run on electricity generated from renewable sources by 2020.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Turing Pharmaceuticals CEO Martin Shkreli, vilified for hiking up the pricing of the drug Daraprim, is back in the news - for livestreaming the day-to-day activities of his life. It is not so riveting.
The day after news broke that Turing Pharmaceuticals' Daraprim has a new competitor on the market, CEO Martin Shkreli announced the company's gotten fast-track status for its experimental epilepsy drug.
San Diego's Imprimis Pharmaceuticals could give Martin Shkreli a run for his money - offering an alternative to the egregiously high cost Daraprim at $1 a pill.
Disclose drug development costs, cap co-pays and pay for (drug) performance. Any takers?
Physicians understand what happens when a profession refuses to heal itself.